Lung Cancer

When others assume that patients with lung cancer must have smoked to get the disease, this stigma can affect patient outcomes.
 

The Food and Drug Administration approved Tecentriq in combination with chemotherapy for the first-line treatment of adults with metastatic non-squamous non-small cell lung cancer without EGFR or ALK mutations.
 

The FDA accepted a supplemental biologics license application (sBLA) and granted a priority review to Imfinzi (durvalumab) for the treatment of patients with previously untreated extensive-stage small cell lung cancer (SCLC), according to AstraZeneca, the drug’s manufacturer.

There is plenty of scientific data about the physical challenges patients with cancer endure, but more is needed to address psychosocial issues.

Patient advocate and lung cancer survivor Nancy Cohen discusses living with stage 4 lung cancer.

Here’s a look at what’s inside our November 2019 Lung Cancer special issue.

How one mother learned that “broken hearts still beat.”

New therapies offer options for patients with non-small cell lung cancer whose disease has spread to the brain.

Paraneoplastic syndromes are uncommon disorders that can arise with any cancer type but are more common with lung cancer.

New therapies approved following innovative research are increasing survival rates for patients with advanced lung cancer.